The pharmacogenetic basis of individual variation in thiopurine metabolism

Personalized Medicine

Volumn 9, Issue 7, 2012, Pages 707-725

  Blaker, Paul Andrew ^a   Arenas Hernandez, Monica ^b   Marinaki, Anthony Marin ^b   Sanderson, Jeremy David ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

azathioprine; genetic; interindividual variation; mercaptopurine; metabolism; pharmacogenetics; thiopurine

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID; RIBAVIRIN; S ADENOSYLMETHIONINE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHROMOSOME 3Q; CLINICAL PRACTICE; CROHN DISEASE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; LEUKEMIA; LEUKOPENIA; PANCREATITIS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84866371286     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.85     Document Type: Review

References (185)

1. Elion GB. The purine path to chemotherapy. Science 244(4900), 41-47 (1989).
2. Hitchings GH, Elion GB, Falco EA, Russell PB, Vanderwerff H. Studies on analogs of purines and pyrimidines. Ann. NY Acad. Sci. 52(8), 1318-1335 (1950).
3. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32(5), 651-662 (1980).
4. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118(6), 1025-1030 (2000).
5. Ansari A, Hassan C, Duley J et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16(10), 1743-1750 (2002).
6. Burchenal JH, Murphy ML, Ellison RR et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8(11), 965-999 (1953).
7. Calne RY. The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine. Lancet 1(7121), 417-418 (1960).
8. Calne RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull. 28, 65-81 (1961).
9. Cheok MH, Pottier N, Kager L, Evans WE. Pharmacogenetics in acute lymphoblastic leukemia. Semin. Hematol. 46(1), 39-51 (2009).
10. Black AJ, Mcleod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129(9), 716-718 (1998).
11. Askanase AD, Wallace DJ, Weisman MH et al. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J. Rheumatol. 36(1), 89-95 (2009).
12. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2, CD000545 (2000).
13. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54(2), 237-241 (2005).
14. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev. (3), CD000301 (2001).
15. Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122(4), 904-915 (2002).
16. Schwab M, Schaffeler E, Marx C et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12(6), 429-436 (2002).
17. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment. Pharmacol. Ther. 22(1), 1-16 (2005).
18. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am. J. Gastroenterol 98(5), 1058-1063 (2003).
19. De Boer NK, Derijks LJ, Gilissen LP et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J. Gastroenterol. 11(35), 5540-5544 (2005).
20. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. (6), CD000545 (2010).
21. Lafolie P, Hayder S, Bjork O, Ahstrom L, Liliemark J, Peterson C. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Acta Paediatr. Scand. 75(5), 797-803 (1986).
22. Zimm S, Collins JM, Riccardi R et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N. Engl. J. Med. 308(17), 1005-1009 (1983).
23. Van Os EC, Zins BJ, Sandborn WJ et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 39(1), 63-68 (1996).
24. Balis FM, Holcenberg JS, Poplack DG et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 92(10), 3569-3577 (1998).
25. Keuzenkamp-Jansen CW, Deabreu RA, Bokkerink JP, Lambooy MA, Trijbels JM. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. J. Pediatr. Hematol. Oncol. 18(2), 145-150 (1996).
26. Rashidi MR, Beedham C, Smith JS, Davaran S. In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Drug Metab. Pharmacokinet. 22(4), 299-306 (2007).
27. Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol. Scand. Suppl. 548, 87-99 (1986).
28. Chalmers AH, Knight PR, Atkinson MR. 6-thiopurines as substrates and inhibitors of purine oxidases: a pathway for conversion of azathioprine into 6-thiouric acid without release of 6-mercaptopurine. Aust. J. Exp. Biol. Med. Sci. 47(2), 263-273 (1969).
29. Jackson PJ. Determination of 6-thiouric acid in human urine. Clin. Biochem. 16(5), 285-286 (1983).
30. Elion EB, Callahan SW, Hitchings GH, Rundles RW, Laszlo J. Experimental, clinical, and metabolic studies of thiopurines. Cancer Chemother. Rep. 16, 197-202 (1962).
31. Elion GB. Significance of azathioprine metabolites. Proc. R. Soc. Med. 65(3), 257-260 (1972).
32. De Miranda P, Beacham LM 3rd, Creagh TH, Elion GB. The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat. J. Pharmacol. Exp. Ther. 187(3), 588-601 (1973).
33. Kurtovic S, Grehn L, Karlsson A, Hellman U, Mannervik B. Glutathione transferase activity with a novel substrate mimics the activation of the prodrug azathioprine. Anal. Biochem. 375(2), 339-344 (2008).
34. McGovern DP, Travis SP, Duley J, Shobowale-Bakre El M, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 122(3), 838-839 (2002).
35. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 35(1), 15-36 (2012).
36. Fotoohi AK, Lindqvist M, Peterson C, Albertioni F. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem. Biophys. Res. Commun. 343(1), 208-215 (2006).
37. Peng XX, Shi Z, Damaraju VL et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk. Res. 32(5), 799-809 (2008).
38. Zaza G, Cheok M, Yang W et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106(5), 1778-1785 (2005).
39. Remy CN. Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J. Biol. Chem. 238, 1078-1084 (1963).
40. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol. Pharmacol. 47(6), 1141-1147 (1995).
41. Neurath MF, Kiesslich R, Teichgraber U et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin. Gastroenterol. Hepatol. 3(10), 1007-1014 (2005).
42. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin. Pharmacokinet. 40(10), 723-751 (2001).
43. Zimmerman TP, Chu LC, Bugge CJ, Nelson DJ, Lyon GM, Elion GB. Identification of 6-methylmercaptopurine ribonucleoside 5'-diphosphate and 5'-triphosphate as metabolites of 6-mercaptopurine in man. Cancer Res. 34(1), 221-224 (1974).
44. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 8(9), 1221-1228 (2007).
45. Brouwer C, Vogels-Mentink TM, Keizer-Garritsen JJ et al. Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment. Clin. Chim. Acta 361(1-2), 95-103 (2005).
46. Rowland K, Lennard L, Lilleyman JS. In vitro metabolism of 6-mercaptopurine by human liver cytosol. Xenobiotica 29(6), 615-628 (1999).
47. De Boer NK, Van Bodegraven AA, Jharap B, De Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4(12), 686-694 (2007).
48. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br. J. Cancer. 68(1), 186-190 (1993).
49. Kroplin T, Iven H. Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase. A comparison of activity in red blood cell samples of 199 blood donors. Eur. J. Clin. Pharmacol. 56(4), 343-345 (2000).
50. Bronk JR, Lister N, Shaw MI. Transport and metabolism of 6-thioguanine and 6-mercaptopurine in mouse small intestine. Clin. Sci. (Lond). 74(6), 629-638 (1988).
51. Kitchen BJ, Moser A, Lowe E et al. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. J. Pharmacol. Exp. Ther. 291(2), 870-874 (1999).
52. Wielinga PR, Reid G, Challa EE et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol. Pharmacol. 62(6), 1321-1331 (2002).
53. Li F, Fridley BL, Matimba A et al. Ecto-5́-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab. Dispos. 38(12), 2329-2338 (2010).
54. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 34(4), 738-746 (1974).
55. Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem. Pharmacol. 35(20), 3533-3541 (1986).
56. Krynetski EY, Krynetskaia NF, Gallo AE, Murti KG, Evans WE. A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol. Pharmacol. 59(2), 367-374 (2001).
57. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 51(2), 143-146 (2002).
58. Poppe D, Tiede I, Fritz G et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176(1), 640-651 (2006).
59. Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111(8), 1133-1145 (2003).
60. Thomas CW, Myhre GM, Tschumper R et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J. Pharmacol. Exp. Ther. 312(2), 537-545 (2005).
61. Aldinucci A, Biagioli T, Manuelli C, Repice AM, Massacesi L, Ballerini C. Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP. J. Neuroimmunol. 218(1-2), 28-35 (2010).
62. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 61(15), 5810-5816 (2001).
63. Coulthard SA, Hogarth LA, Little M et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol. Pharmacol. 62(1), 102-109 (2002).
64. Tay BS, Lilley RM, Murray AW, Atkinson MR. Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem. Pharmacol. 18(4), 936-938 (1969).
65. Bokkerink JP, Stet EH, De Abreu RA et al. 6-mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem. Pharmacol. 45(7), 1455-1463 (1993).
66. De Abreu R, Lambooy L, Stet E, Vogels-Mentink T, Van Den Heuvel L. Thiopurine induced disturbance of DNA methylation in human malignant cells. Adv. Enzyme Regul. 35, 251-263 (1995).
67. Wang H, Wang Y. 6-thioguanine perturbs cytosine methylation at the CpG dinucleotide site by DNA methyltransferases in vitro and acts as a DNA demethylating agent in vivo. Biochemistry 48(10), 2290-2299 (2009).
68. Yuan B, Zhang J, Wang H et al. 6-thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1. Cancer Res. 71(5), 1904-1911 (2011).
69. Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 53(8), 1123-1128 (2004).
70. Kaskas BA, Louis E, Hindorf U et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 52(1), 140-142 (2003).
71. Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther. Drug Monit. 27(5), 647-654 (2005).
72. Lennard L, Maddocks JL. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J. Pharm. Pharmacol. 35(1), 15-18 (1983).
73. Welch J, Lennard L, Morton GC, Lilleyman JS. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose. Ther. Drug Monit. 19(4), 382-385 (1997).
74. Lennard L, Welch J, Lilleyman JS. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites. Br. J. Clin. Pharmacol. 42(4), 525-527 (1996).
75. Roblin X, Serre-Debeauvais F, Phelip JM et al. 6-thioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment. Pharmacol. Ther. 21(7), 829-839 (2005).
76. Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment. Pharmacol. Ther. 34(5), 544-554 (2011).
77. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. 1983. Br. J. Clin. Pharmacol. 58(7), S867-S871; discussion S872-S864 (2004).
78. Gisbert JP, Gonzalez-Lama Y, Mate J. [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease]. Gastroenterol. Hepatol. 29(9), 568-583 (2006).
79. Cuffari C, Theoret Y, Latour S, Seidman G. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 39(3), 401-406 (1996).
80. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4), 705-713 (2000).
81. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130(4), 1047-1053 (2006).
82. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 24(2), 331-342 (2006).
83. Hindorf U, Lindqvist M, Peterson C et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 55(10), 1423-1431 (2006).
84. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther. 41(1), 18-25 (1987).
85. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001-2008 (1999).
86. Dervieux T, Boulieu R. Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clin. Chem. 44(12), 2511-2515 (1998).
87. De Graaf P, Vos RM, De Boer NH et al. Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 878(19), 1437-1442 (2010).
88. Bergan S, Bentdal O, Sodal G, Brun A, Rugstad HE, Stokke O. Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther. Drug Monit. 19(5), 502-509 (1997).
89. Liliemark J, Pettersson B, Engberg B, Lafolie P, Masquelier M, Peterson C. On the paradoxically concentration-dependent metabolism of 6-mercaptopurine in WEHI-3b murine leukemia cells. Cancer Res. 50(1), 108-112 (1990).
90. Herrlinger KR, Fellermann K, Fischer C et al. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease. Aliment. Pharmacol. Ther. 19(12), 1269-1276 (2004).
91. Lancaster DL, Patel N, Lennard L, Lilleyman JS. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother. Pharmacol. 50(1), 33-36 (2002).
92. Deibert P, Dilger K, Fischer C et al. High variation of tioguanine absorption in patients with chronic active Crohn's disease. Aliment. Pharmacol. Ther. 18(2), 183-189 (2003).
93. De Boer NK, Derijks LJ, Keizer-Garritsen JJ et al. Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease. J. Clin. Pharmacol. 47(2), 187-191 (2007).
94. Hindorf U, Lyrenas E, Nilsson A, Schmiegelow K. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand. J. Gastroenterol. 39(11), 1105-1112 (2004).
95. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev. Gastroenterol. Disord. 3(Suppl. 1), S30-38 (2003).
96. Van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment. Pharmacol. Ther. 35(10), 1181-1189 (2012).
97. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48(5), 642-646 (2001).
98. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2(5), 410-417 (2004).
99. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J. Crohns Colitis doi:10.1016/j.crohns.2012.02. 007 (2012) (Epub ahead of print).
100. Shih DQ, Nguyen M, Zheng L et al. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment. Pharmacol. Ther. doi:10.1111/j.1365-2036.2012.05206.x. (2012) (Epub ahead of print).
101. Elion GB. Nobel Lecture. The purine path to chemotherapy. Biosci. Rep. 9(5), 509-529 (1989).
102. Chocair P, Duley J, Simmonds HA et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 342(8863), 83-84 (1993).
103. Chrzanowska M, Krzymanski M. Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine. Ther. Drug Monit. 21(2), 231-237 (1999).
104. Sparrow MP, Hande SA, Friedman S et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. 22(5), 441-446 (2005).
105. Blaker P, Arenas M, Fairbanks L, Irving P, Marinaki A, Sanderson J. A biochemical mechanism for the role of allopurinol in TPMT inhibition. Gut 60(s1), A132-A133 (2011).
106. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 39(4), 456-459 (1995).
107. Hande S, Wilson-Rich N, Bousvaros A et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm. Bowel Dis. 12(4), 251-257 (2006).
108. Gilissen LP, Bierau J, Derijks LJ et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment. Pharmacol. Ther. 22(7), 605-611 (2005).
109. Actis GC, Pellicano R, Rizzetto M et al. Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J. Gastroenterol. 15(12), 1420-1426 (2009).
110. Gao X, Zhang FB, Ding L et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur. J. Gastroenterol. Hepatol. 24(8), 958-964 (2012).
111. De Graaf P, De Boer N, Wong D et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br. J. Pharmacol. 160(5), 1083-1091 (2010).
112. Ansari A, Aslam Z, De Sica A et al. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment. Pharmacol. Ther. 28(6), 749-757 (2008).
113. Dilger K, Schaeffeler E, Lukas M et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther. Drug Monit. 29(1), 1-5 (2007).
114. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur. J. Clin. Pharmacol. 49(5), 393-396 (1996).
115. Oselin K, Anier K. Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metab. Dispos. 35(9), 1452-1454 (2007).
116. Roblin X, Serre-Debeauvais F, Phelip JM, Bessard G, Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment. Pharmacol. Ther. 18(9), 917-925 (2003).
117. Bokkerink JP, Damen FJ, Hulscher MW, Bakker MA, De Abreu RA. Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia. Haematol. Blood Transfus. 33, 110-117 (1990).
118. Stet EH, De Abreu RA, Janssen YP, Bokkerink JP, Trijbels FJ. A biochemical basis for synergism of 6-mercaptopurine and mycophenolic acid in Molt F4, a human malignant T-lymphoblastic cell line. Biochim. Biophys. Acta 1180(3), 277-282 (1993).
119. Peyrin-Biroulet L, Cadranel JF, Nousbaum JB et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment. Pharmacol. Ther. 28(8), 984-993 (2008).
120. Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol. Pharmacol. 70(2), 747-754 (2006).
121. Cotton SC, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am. J. Epidemiol. 151(1), 7-32 (2000).
122. Stocco G, Martelossi S, Barabino A et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13(1), 57-64 (2007).
123. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22(47), 7369-7375 (2003).
124. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig. Dis. Sci. 45(9), 1810-1813 (2000).
125. Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 27(3), 220-227 (2008).
126. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM 95(7), 439-444 (2002).
127. Krynetski EY, Fessing MY, Yates CR, Sun D, Schuetz JD, Evans WE. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. Pharm. Res. 14(12), 1672-1678 (1997).
128. Szumlanski C, Otterness D, Her C et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15(1), 17-30 (1996).
129. Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J. Hum. Genet. 45(5), 299-302 (2000).
130. Lee D, Szumlanski C, Houtman J et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21. 1. Drug Metab. Dispos. 23(3), 398-405 (1995).
131. Landy J, Bhuva N, Marinaki A, Mawdsley J. Novel thiopurine methyltransferase variant TPMT*28 results in a misdiagnosis of TPMT deficiency. Inflamm. Bowel Dis. 17(6), 1441-1442 (2011).
132. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl Acad. Sci. USA 92(4), 949-953 (1995).
133. Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin JG, Schwab M. Highly multiplexed genotyping of thiopurine S-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin. Chem. 54(10), 1637-1647 (2008).
134. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, Mcleod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum. Mol. Genet. 8(2), 367-370 (1999).
135. Coulthard SA, Howell C, Robson J, Hall AG. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 92(8), 2856-2862 (1998).
136. Van Loon JA, Szumlanski CL, Weinshilboum RM. Human kidney thiopurine methyltransferase. Photoaffinity labeling with S-adenosyl-l-methionine. Biochem. Pharmacol. 44(4), 775-785 (1992).
137. Giverhaug T, Klemetsdal B, Lysaa R, Aarbakke J. Intraindividual variability in red blood cell thiopurine methyltransferase activity. Eur. J. Clin. Pharmacol. 50(3), 217-220 (1996).
138. Mcleod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85(7), 1897-1902 (1995).
139. Lindqvist M, Hindorf U, Almer S et al. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 25(9-11), 1033-1037 (2006).
140. Arenas M, Duley JA, Ansari A et al. Genetic determinants of the pre-and post-azathioprine therapy thiopurine methyltransferase activity phenotype. Nucleosides Nucleotides Nucleic Acids 23(8-9), 1403-1405 (2004).
141. Fessing MY, Krynetski EY, Zambetti GP, Evans WE. Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. Eur. J. Biochem. 256(3), 510-517 (1998).
142. Spire-Vayron De La Moureyre C, Debuysere H, Fazio F et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 9(2), 189-198 (1999).
143. Kotur N, Stankovic B, Kassela K et al. 6-mercaptopurine influences TPMT gene transcription in a TPMT gene promoter variable number of tandem repeats-dependent manner. Pharmacogenomics 13(3), 283-295 (2012).
144. Zukic B, Radmilovic M, Stojiljkovic M et al. Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription. Pharmacogenomics 11(4), 547-557 (2010).
145. Alves S, Amorim A, Ferreira F, Prata MJ. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin. Pharmacol. Ther. 70(2), 165-174 (2001).
146. Marinaki AM, Arenas M, Khan ZH et al. Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 13(2), 97-105 (2003).
147. Karas-Kuzelicki N, Mlinaric-Rascan I. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. Pharmacogenomics 10(8), 1309-1322 (2009).
148. Scheuermann TH, Keeler C, Hodsdon ME. Consequences of binding an S-adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone. Biochemistry 43(38), 12198-12209 (2004).
149. Ogino S, Wilson RB. Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J. Hum. Genet. 48(1), 1-7 (2003).
150. Arenas M, Simpson G, Lewis CM et al. Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin. Chem. 51(12), 2371-2374 (2005).
151. Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 23(5), 971-974 (2009).
152. Serre-Debeauvais F, Bayle F, Amirou M et al. [Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation]. Presse Med. 24(21), 987-988 (1995).
153. Grant DM, Tang BK, Campbell ME, Kalow W. Effect of allopurinol on caffeine disposition in man. Br. J. Clin. Pharmacol. 21(4), 454-458 (1986).
154. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin. Pharmacol. Ther. 50(6), 663-672 (1991).
155. Kudo M, Sasaki T, Ishikawa M, Hirasawa N, Hiratsuka M. Kinetics of 6-thioxanthine metabolism by allelic variants of xanthine oxidase. Drug Metab. Pharmacokinet. 25(4), 361-366 (2010).
156. Kelley WN, Rosenbloom FM, Seegmiller JE. The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism. J. Clin. Invest. 46(9), 1518-1529 (1967).
157. Pieters R, Huismans DR, Loonen AH et al. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int. J. Cancer. 51(2), 213-217 (1992).
158. Ding L, Zhang FB, Liu H et al. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis. 18(1), 63-73 (2012).
159. Brennand J, Caskey CT. The molecular basis of genetically acquired resistance to purine analogues in cultured mammalian cells. In: Antitumour Drug Resistance. Fox BW, Fox M (Eds). Springer-Verlag, NY, USA, 88-99 (1985).
160. De Boer NK, Van Asseldonk DP, Van Bodegraven AA. On the malignant potential of thiopurine therapy. Blood 113(24), 6258; author reply 6258-6259 (2009).
161. Leleiko NS, Martin BA, Walsh M, Kazlow P, Rabinowitz S, Sterling K. Tissue-specific gene expression results from a purine-and pyrimidine-free diet
162. Elion GB. Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed. Proc. 26(3), 898-904 (1967).
163. Glesne DA, Huberman E. Cloning and sequence of the human type II IMP dehydrogenase gene. Biochem. Biophys. Res. Commun. 205(1), 537-544 (1994).
164. Glander P, Hambach P, Braun KP et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. 4(12), 2045-2051 (2004).
165. Jain J, Almquist SJ, Ford PJ et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem. Pharmacol. 67(4), 767-776 (2004).
166. Zimmermann AG, Wright KL, Ting JP, Mitchell BS. Regulation of inosine-5́-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5' palindromic octamer sequence. J. Biol. Chem. 272(36), 22913-22923 (1997).
167. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J. 7(5), 312-317 (2007).
168. Haglund S, Taipalensuu J, Peterson C, Almer S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease-relation to TPMT activity and metabolite concentrations. Br. J. Clin. Pharmacol. 65(1), 69-77 (2008).
169. Sumi S, Marinaki AM, Arenas M et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 111(4-5), 360-367 (2002).
170. Behmanesh M, Sakumi K, Abolhassani N et al. ITPase-deficient mice show growth retardation and die before weaning. Cell Death Differ. 16(10), 1315-1322 (2009).
171. Duley JA, Simmonds HA, Hopkinson DA, Levinsky RJ. Inosine triphosphate pyrophosphohydrolase deficiency in a kindred with adenosine deaminase deficiency. Clin. Chim. Acta 188(3), 243-252 (1990).
172. Ansari A, Arenas M, Greenfield SM et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 28(8), 973-983 (2008).
173. Zelinkova Z, Derijks LJ, Stokkers PC et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 4(1), 44-49 (2006).
174. Okada Y, Nakamura K, Hiromura K, Nojima Y, Horiuchi R, Yamamoto K. Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus. Clin. Pharmacol. Ther. 85(5), 527-530 (2009).
175. Stocco G, Cheok MH, Crews KR et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85(2), 164-172 (2009).
176. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14(11), 779-781 (2004).
177. Stocco G, Crews KR, Evans WE. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf. 9(1), 23-37 (2010).
178. Karim H, Hashemi J, Larsson C, Moshfegh A, Fotoohi AK, Albertioni F. The pattern of gene expression and gene dose profiles of 6-mercaptopurine-and 6-thioguanine-resistant human leukemia cells. Biochem. Biophys. Res. Commun. 411(1), 156-161 (2011).
179. Spector T, Jones TE, Lafon SW, Nelson DJ, Berens RL, Marr JJ. Monophosphates of formycin B and allopurinol riboside. Interactions with leishmanial and mammalian succino-AMP synthetase and GMP reductase. Biochem. Pharmacol. 33(10), 1611-1617 (1984).
180. Kerstens PJ, Stolk JN, De Abreu RA, Lambooy LH, Van De Putte LB, Boerbooms AA. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 142-145 (1995).
181. Pieters R, Huismans DR, Loonen AH et al. Relation of 5́- nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. Leuk. Res. 16(9), 873-880 (1992).
182. Mendoza JL, Urcelay E, Lana R et al. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflamm. Bowel Dis. 13(5), 585-590 (2007).
183. Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippe J. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur. J. Cancer. 42(3), 295-309 (2006).
184. Krishnamurthy P, Schwab M, Takenaka K et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 68(13), 4983-4989 (2008).
185. Ban H, Andoh A, Imaeda H et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J. Gastroenterol. 45(10), 1014-1021 (2010).